{"id":1021315,"date":"2026-11-16T09:20:23","date_gmt":"2026-11-16T14:20:23","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/xortx-completes-manufacturing-of-clinical-drug-supply\/"},"modified":"2026-11-16T09:20:23","modified_gmt":"2026-11-16T14:20:23","slug":"xortx-completes-manufacturing-of-clinical-drug-supply","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/xortx-completes-manufacturing-of-clinical-drug-supply\/","title":{"rendered":"XORTX Completes Manufacturing of Clinical Drug Supply"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"center\">\n        <strong>\u25cf Clinical Drug Supply and Packaging completed in preparation\u00a0<\/strong><br \/>\n        <strong>for the XRX-OXY-102 Clinical Study \u25cf<\/strong>\n      <\/p>\n<p align=\"justify\">CALGARY, Alberta, Nov.  16, 2026  (GLOBE NEWSWIRE) &#8212; XORTX Therapeutics Inc. (\u201c<strong>XORTX<\/strong>\u201d or the \u201c<strong>Company<\/strong>\u201d) (NASDAQ: XRTX), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, is pleased to announce that manufacturing and packaging of clinical drug supply for the XRX-OXY-102 clinical trial has been completed. Production of XORTX\u2019s clinical drug supply is based on proprietary synthetic pathway for production of high yield pure oxypurinol, then formulated using our proprietary and patented formulation of this drug. This process to produce the formulation and tablet format the Company aims to advance through marketing approval is a key step forward for the XRx-026 program for the treatment of gout.<\/p>\n<p align=\"justify\">The XRx-026 program is our lead program focused on the treatment of individuals with symptoms of gout.\u00a0In parallel with the manufacturing processes, method development and validation of tablet, drug development team activities include the preparation of the Clinical Trial Application (\u201c<strong>CTA<\/strong>\u201d) for filing with Health Canada. Validation data from this manufacturing process will be included in the CTA. The application describes the Company\u2019s clinical development plan for XRx-026 and its intention to advance the program toward regulatory approval in Canada in parallel with its planned Investigational New Drug (\u201c<strong>IND<\/strong>\u201d) application filing with the US Food and Drug Administration (\u201c<strong>FDA<\/strong>\u201d).<\/p>\n<p align=\"justify\">\n        <strong>About the XRX-OXY-102 program<\/strong>\n      <\/p>\n<p align=\"justify\">Part 1 of the XRX-OXY-102 clinical trial builds upon the previously reported positive clinical results for the proprietary XORLO\u2122 formulation and extends characterization of the commercial tablet form. Part 1 of the study will characterizing the steady state pharmacokinetics of XORLO\u2122, XORTX\u2019s commercial form of oxypurinol tablet. Part 2 of the study will evaluate the therapeutic equivalence of XORLO compared to allopurinol in gout patients. Data generated during this study will support the planned marketing application (\u201c<strong>NDA<\/strong>\u201d) submission to the FDA. XORTX intends to advance this drug to marketing approval pending favorable clinical study results and its FDA discussions. Once completed, a commercial drug supply is a pre-requisite for FDA approval for marketing of XORLO\u2122.<\/p>\n<p align=\"justify\">\n        <strong>About Hyperuricemia and Gout<\/strong>\n      <\/p>\n<p align=\"justify\">In the United States, approximately <strong>44 million individuals<\/strong> have uric acid levels above the normal range, with <strong>9.2 million individuals living with gout<\/strong><sup>1<\/sup>. Gout is associated with severe pain, reduced quality of life<sup>2<\/sup>, decreased physical function<sup>3<\/sup>, increased healthcare costs<sup>4<\/sup>, and lost economic productivity<sup>5<\/sup>. It is also strongly associated with metabolic syndrome<sup>5<\/sup>, myocardial infarction<sup>6,7<\/sup>, Type 2 diabetes mellitus<sup>8<\/sup>, chronic kidney disease<sup>9<\/sup>, and premature mortality<sup>6,10,11<\/sup>. Importantly, the global prevalence of gout is increasing, with cases expected to increase 70% over the next 25 years<sup>*<\/sup>.<\/p>\n<p align=\"justify\">\n        <strong>About the XRx-026 Program and XORLO\u2122<\/strong>\n      <\/p>\n<p align=\"justify\">The XRx-026 program is developing XORLO\u2122, the Company\u2019s proprietary formulation of oxypurinol, to treat individuals with gout. Oral xanthine oxidase inhibitors (\u201c<strong>XOIs<\/strong>\u201d) are the current standard of care for treating hyperuricemia-associated gout. Allopurinol is the recommended first-line therapy for gout; however, limitations remain: approximately 3\u20135% of patients cannot tolerate allopurinol. An alternative XOI, febuxostat, at one time achieved annual peak net sales &gt;US$450 million, and now carries a boxed warning for cardiovascular risk which has substantially decreased its use and sales. XORLO\u2122 is designed to address this unmet need by providing an alternative therapeutic option with a differentiated safety and efficacy profile. Advancement of XRx-026 through the planned CTA and NDA filings is a strategic priority for XORTX.<\/p>\n<p align=\"justify\">\n        <strong>References<\/strong>\n      <\/p>\n<ol style=\"list-style-type:decimal\">\n<li style=\"text-align:justify\">Chen-Xu M, et al. Prevalence of Gout and Hyperuricemia in the US. <em>Arthritis Rheumatol.<\/em> 2019;71(6):991\u2013999.<\/li>\n<li style=\"text-align:justify\">Singh JA. Quality of life and quality of care for patients with gout. <em>Curr Rheumatol Rep.<\/em> 2009;11(2):154\u201360.<\/li>\n<li style=\"text-align:justify\">Burke BT, et al. Physical Function, Hyperuricemia, and Gout in Older Adults. <em>Arthritis Care Res.<\/em> 2015;67(12):1730\u20138.<\/li>\n<li style=\"text-align:justify\">Rai SK, et al. The economic burden of gout: a systematic review. <em>Semin Arthritis Rheum.<\/em> 2015;45(1):75\u201380.<\/li>\n<li style=\"text-align:justify\">Choi HK, et al. Prevalence of the metabolic syndrome in individuals with hyperuricemia. <em>Am J Med.<\/em> 2007;120(5):442\u20137.<\/li>\n<li style=\"text-align:justify\">Choi HK, Curhan G. Independent impact of gout on mortality and risk for coronary heart disease. <em>Circulation.<\/em> 2007;116(8):894\u2013900.<\/li>\n<li style=\"text-align:justify\">Liu S-C, et al. Gout and Risk of Myocardial Infarction: A Systematic Review. <em>PLoS ONE.<\/em> 2015;10(7):e0134088.<\/li>\n<li style=\"text-align:justify\">Choi HK, et al. Gout and the risk of type 2 diabetes among men with high cardiovascular risk profile. <em>Rheumatology.<\/em> 2008;47(10):1567\u201370.<\/li>\n<li style=\"text-align:justify\">Roughley MJ, et al. Gout and risk of chronic kidney disease and nephrolithiasis: meta-analysis. <em>Arthritis Res Ther.<\/em> 2015;17(1).<\/li>\n<li style=\"text-align:justify\">Kuo C-F, et al. Gout: an independent risk factor for all-cause and cardiovascular mortality. <em>Rheumatology.<\/em> 2010;49(1):141\u20136.<\/li>\n<li style=\"text-align:justify\">Fisher MC, et al. Premature mortality gap in gout: a general population-based study. <em>Ann Rheum Dis.<\/em> 2017;76(7):1289\u201394.<\/li>\n<\/ol>\n<p align=\"justify\">\n        <strong>About XORTX Therapeutics Inc.<\/strong>\n      <\/p>\n<p align=\"justify\">XORTX is a pharmaceutical company with three clinically advanced products in development: 1) our lead XRx-026 program for the treatment of gout; 2) XRx-008 program for ADPKD; and 3) XRx-101 for acute kidney and other acute organ injury associated with respiratory virus infections. In addition, the Company is developing XRx-225, a pre-clinical stage program for Type 2 diabetic nephropathy, and the recently acquired VB4-P5 program, which is currently at the\u00a0pre-IND stage of development and targets both rare and prevalent forms of kidney disease. XORTX is working to advance products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. At XORTX, we are dedicated to developing medications that improve the quality of life and health of individuals with gout and other important diseases.<\/p>\n<p align=\"justify\">For more information, please contact:<\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"max-width:35%;width:35%;min-width:35%;padding-left: 0;text-align: left;vertical-align: middle;vertical-align: bottom\">Allen Davidoff, Co-CEO<\/td>\n<td style=\"max-width:65%;width:65%;min-width:65%;padding-left: 0;text-align: left;vertical-align: middle;vertical-align: bottom\">Mika Grasso, Co-CEO<\/td>\n<\/tr>\n<tr>\n<td style=\"padding-left: 0;text-align: left;vertical-align: middle;vertical-align: bottom\">\n            <a href=\"mailto:adavidoff@xortx.com\" rel=\"nofollow\" target=\"_blank\"><br \/>\n              <u>adavidoff@xortx.com<\/u><br \/>\n            <\/a>\n          <\/td>\n<td style=\"padding-left: 0;text-align: left;vertical-align: middle;vertical-align: bottom\">\n            <a href=\"mailto:mgrasso@xortx.com\" rel=\"nofollow\" target=\"_blank\"><br \/>\n              <u>mgrasso@xortx.com<\/u><br \/>\n            <\/a>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"padding-left: 0;text-align: left;vertical-align: middle;vertical-align: bottom\">+1 403 455 7727<\/td>\n<td style=\"padding-left: 0;text-align: left;vertical-align: middle;vertical-align: bottom\">+1 949 244 6011<\/td>\n<\/tr>\n<tr>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<\/tr>\n<\/table>\n<p align=\"justify\">\n        <strong>Forward-Looking Statements<\/strong>\n      <\/p>\n<p align=\"justify\">This press release contains \u201cforward-looking statements\u201d within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, as well as \u201cforward-looking information\u201d within the meaning of applicable Canadian securities laws. Forward-looking statements may be identified by the use of words such as \u201canticipate,\u201d \u201cbelieve,\u201d \u201cexpect,\u201d \u201cestimate,\u201d \u201cplan,\u201d \u201cintend,\u201d \u201cwill,\u201d \u201cmay,\u201d \u201cpotential,\u201d \u201clooks forward,\u201d and similar expressions, and include all statements that are not statements of historical fact. These forward-looking statements include, but are not limited to, statements regarding the payment of the registration fee for, and the registration and issuance of, the Japanese Patent; the anticipated term, expiry date and scope of the Japanese Patent, including the availability of any patent term extension; the protection the Japanese Patent may provide for the XRx-101 program and the Company\u2019s other product candidates; the size, composition and strength of the Company\u2019s patent portfolio and its plans to continue to build that portfolio; the Company\u2019s evaluation of, and the potential for, partnering or licensing arrangements for the XRx-101 program and its other programs; the potential for xanthine oxidase inhibition to attenuate increases in uric acid and acute kidney injury associated with respiratory viral infection; and the advancement of the Company\u2019s XRx-101 and XRx-026 programs, its other development programs, and its strategy.<\/p>\n<p align=\"justify\">Forward-looking statements are based on the Company\u2019s current expectations and assumptions and are subject to known and unknown risks, uncertainties, and other factors that could cause actual results, performance, or achievements to differ materially from those expressed or implied by such statements. Such risks and uncertainties include, among others: the risk that the registration fee is not paid or that the Japanese Patent is otherwise not registered and issued as anticipated, or at all; the risk that the Japanese Patent, once issued, is challenged, narrowed, invalidated or held unenforceable, including in post-grant opposition or invalidation proceedings before the JPO; the risk that the claims of the Japanese Patent do not cover competing products or provide meaningful commercial protection; the risk that no patent term extension is available for the Japanese Patent; the risk that the Company\u2019s pending patent applications do not issue as patents, or issue with claims narrower than those sought; the Company\u2019s ability to obtain, maintain, defend and enforce its intellectual property rights in Japan and other jurisdictions, including its ability to fund annuity and maintenance fees; the Company\u2019s need for, and ability to obtain, additional capital to fund its development programs and operations; the risk that the XRx-101 program, which is not the Company\u2019s lead program, is not further developed, partnered or approved in Japan or any other jurisdiction; the risk that the Company does not enter into any partnering or licensing arrangement on acceptable terms, or at all; the risk that xanthine oxidase inhibition does not prove to be safe or effective in treating or preventing acute kidney injury or other acute organ injury associated with viral infection; the Company\u2019s ability to advance, and obtain regulatory approval for, the XRx-026 program and its other product candidates on the timelines currently anticipated, or at all; the evolving regulatory environment applicable to the Company\u2019s business in the United States, Canada and Japan; the Company\u2019s ability to maintain the listing of its common shares on the Nasdaq Capital Market; and the Company\u2019s ability to attract and retain qualified personnel.<\/p>\n<p align=\"justify\">For a more detailed discussion of these and other risks and uncertainties, investors should review the disclosures contained under the heading \u201cRisk Factors\u201d in the Company\u2019s Annual Report on Form 20-F for the fiscal year ended December 31, 2025, and in the Company\u2019s subsequent Reports of Foreign Private Issuer on Form 6-K, each as filed with or furnished to the U.S. Securities and Exchange Commission (the \u201c<strong>SEC<\/strong>\u201d) and available at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=qDa3GJQwb2PY9CwWqRJfJrn3epkpKoXHdpe7zvcYXiDR7uToELS8wfWD2IkLuJaR6zO2cty1MrNP1GLFFgI9EA==\" rel=\"nofollow\" target=\"_blank\"><u>www.sec.gov<\/u><\/a>, as well as in the Company\u2019s continuous disclosure documents filed with the Canadian securities regulatory authorities and available at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=qDa3GJQwb2PY9CwWqRJfJmwpvhdLXP2pJscKJ3lp2q4MapEGw4FifROIZH-vPZEsv_uao2fqIA5CWgQMI4Ls9CKvx9iIpFFIDX2to-TmTIk=\" rel=\"nofollow\" target=\"_blank\"><u>www.sedarplus.ca<\/u><\/a>.<\/p>\n<p align=\"justify\">The forward-looking statements in this press release speak only as of the date hereof. Except as required by law, the Company undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. Readers are cautioned not to place undue reliance on these forward-looking statements.<\/p>\n<p align=\"justify\">\n        <u>\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0<br \/><\/u>*\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=YeYyfi1n9NvlmvPTbbIG_CKcD9jfSofqpeeX9WpKq1WfQHxXlUhsjRz6SSen92dSx6v5n90bc-qX3EKrhLaZ_EXkiDah9VvkZIvUwqK_4kt55w6wEkILUVpxtyXG5nPwthDAKYjNqQkp8eVF0G6U3Q==\" rel=\"nofollow\" target=\"_blank\"><u>https:\/\/pubmed.ncbi.nlm.nih.gov\/38996590\/<\/u><\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3ODA1MCM3OTY3MTQ5IzIwOTcyNzk=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MDcyMGE1ZjUtNGFjMy00MzkyLTljMzYtYWZmOGQxMDI5MDNjLTExMDg4NTAtMjAyNi0xMS0xNi1lbg==\/tiny\/XORTX-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>\u25cf Clinical Drug Supply and Packaging completed in preparation\u00a0 for the XRX-OXY-102 Clinical Study \u25cf CALGARY, Alberta, Nov. 16, 2026 (GLOBE NEWSWIRE) &#8212; XORTX Therapeutics Inc. (\u201cXORTX\u201d or the \u201cCompany\u201d) (NASDAQ: XRTX), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, is pleased to announce that manufacturing and packaging of clinical drug supply for the XRX-OXY-102 clinical trial has been completed. Production of XORTX\u2019s clinical drug supply is based on proprietary synthetic pathway for production of high yield pure oxypurinol, then formulated using our proprietary and patented formulation of this drug. This process to produce the formulation and tablet format the Company aims to advance through marketing approval is a key step &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/xortx-completes-manufacturing-of-clinical-drug-supply\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;XORTX Completes Manufacturing of Clinical Drug Supply&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1021315","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>XORTX Completes Manufacturing of Clinical Drug Supply - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/xortx-completes-manufacturing-of-clinical-drug-supply\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"XORTX Completes Manufacturing of Clinical Drug Supply - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"\u25cf Clinical Drug Supply and Packaging completed in preparation\u00a0 for the XRX-OXY-102 Clinical Study \u25cf CALGARY, Alberta, Nov. 16, 2026 (GLOBE NEWSWIRE) &#8212; XORTX Therapeutics Inc. (\u201cXORTX\u201d or the \u201cCompany\u201d) (NASDAQ: XRTX), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, is pleased to announce that manufacturing and packaging of clinical drug supply for the XRX-OXY-102 clinical trial has been completed. Production of XORTX\u2019s clinical drug supply is based on proprietary synthetic pathway for production of high yield pure oxypurinol, then formulated using our proprietary and patented formulation of this drug. This process to produce the formulation and tablet format the Company aims to advance through marketing approval is a key step &hellip; Continue reading &quot;XORTX Completes Manufacturing of Clinical Drug Supply&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/xortx-completes-manufacturing-of-clinical-drug-supply\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-16T14:20:23+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3ODA1MCM3OTY3MTQ5IzIwOTcyNzk=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"8 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xortx-completes-manufacturing-of-clinical-drug-supply\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xortx-completes-manufacturing-of-clinical-drug-supply\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"XORTX Completes Manufacturing of Clinical Drug Supply\",\"datePublished\":\"2026-11-16T14:20:23+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xortx-completes-manufacturing-of-clinical-drug-supply\\\/\"},\"wordCount\":1609,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xortx-completes-manufacturing-of-clinical-drug-supply\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3ODA1MCM3OTY3MTQ5IzIwOTcyNzk=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xortx-completes-manufacturing-of-clinical-drug-supply\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xortx-completes-manufacturing-of-clinical-drug-supply\\\/\",\"name\":\"XORTX Completes Manufacturing of Clinical Drug Supply - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xortx-completes-manufacturing-of-clinical-drug-supply\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xortx-completes-manufacturing-of-clinical-drug-supply\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3ODA1MCM3OTY3MTQ5IzIwOTcyNzk=\",\"datePublished\":\"2026-11-16T14:20:23+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xortx-completes-manufacturing-of-clinical-drug-supply\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xortx-completes-manufacturing-of-clinical-drug-supply\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xortx-completes-manufacturing-of-clinical-drug-supply\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3ODA1MCM3OTY3MTQ5IzIwOTcyNzk=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3ODA1MCM3OTY3MTQ5IzIwOTcyNzk=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xortx-completes-manufacturing-of-clinical-drug-supply\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"XORTX Completes Manufacturing of Clinical Drug Supply\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"XORTX Completes Manufacturing of Clinical Drug Supply - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/xortx-completes-manufacturing-of-clinical-drug-supply\/","og_locale":"en_US","og_type":"article","og_title":"XORTX Completes Manufacturing of Clinical Drug Supply - Market Newsdesk","og_description":"\u25cf Clinical Drug Supply and Packaging completed in preparation\u00a0 for the XRX-OXY-102 Clinical Study \u25cf CALGARY, Alberta, Nov. 16, 2026 (GLOBE NEWSWIRE) &#8212; XORTX Therapeutics Inc. (\u201cXORTX\u201d or the \u201cCompany\u201d) (NASDAQ: XRTX), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, is pleased to announce that manufacturing and packaging of clinical drug supply for the XRX-OXY-102 clinical trial has been completed. Production of XORTX\u2019s clinical drug supply is based on proprietary synthetic pathway for production of high yield pure oxypurinol, then formulated using our proprietary and patented formulation of this drug. This process to produce the formulation and tablet format the Company aims to advance through marketing approval is a key step &hellip; Continue reading \"XORTX Completes Manufacturing of Clinical Drug Supply\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/xortx-completes-manufacturing-of-clinical-drug-supply\/","og_site_name":"Market Newsdesk","article_published_time":"2026-11-16T14:20:23+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3ODA1MCM3OTY3MTQ5IzIwOTcyNzk=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"8 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xortx-completes-manufacturing-of-clinical-drug-supply\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xortx-completes-manufacturing-of-clinical-drug-supply\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"XORTX Completes Manufacturing of Clinical Drug Supply","datePublished":"2026-11-16T14:20:23+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xortx-completes-manufacturing-of-clinical-drug-supply\/"},"wordCount":1609,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xortx-completes-manufacturing-of-clinical-drug-supply\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3ODA1MCM3OTY3MTQ5IzIwOTcyNzk=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xortx-completes-manufacturing-of-clinical-drug-supply\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/xortx-completes-manufacturing-of-clinical-drug-supply\/","name":"XORTX Completes Manufacturing of Clinical Drug Supply - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xortx-completes-manufacturing-of-clinical-drug-supply\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xortx-completes-manufacturing-of-clinical-drug-supply\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3ODA1MCM3OTY3MTQ5IzIwOTcyNzk=","datePublished":"2026-11-16T14:20:23+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xortx-completes-manufacturing-of-clinical-drug-supply\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/xortx-completes-manufacturing-of-clinical-drug-supply\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xortx-completes-manufacturing-of-clinical-drug-supply\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3ODA1MCM3OTY3MTQ5IzIwOTcyNzk=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3ODA1MCM3OTY3MTQ5IzIwOTcyNzk="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xortx-completes-manufacturing-of-clinical-drug-supply\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"XORTX Completes Manufacturing of Clinical Drug Supply"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1021315","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1021315"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1021315\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1021315"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1021315"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1021315"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}